Ember Therapeutics, Inc. (OTCPK: EMBT, the “Company”), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that on October 1, 2018 the Company voluntarily filed a Form 15 with the United States Securities and Exchange Commission
October 1, 2018
· 3 min read